|
Technology
A fundamental problem in the detection of aggregated misfolded proteins (AMPs) in peripheral blood is the presence of the normal protein at a million-fold relative concentration. The company has acquired all rights to a process using chemical modifying agents that alter epitopes on normal proteins but not on AMPs (see Figure). This procedure minimizes the background and once the aggregate has been disaggregated, the conserved epitopes can then be detected by ultra-sensitive immunodetection procedures using standard reagents. This process can be applied to any AMP and overcomes the fundamental problem of having to detect AMPs in a solution of proteins where normal proteins are much more prevalent. The company has verified that EP technologies selectively modify normal protein but not AMPs in samples from Transmissible Spongiform Encephalopathies (TSE) and Alzheimer’s Disease (AD).
|
